Pharma company Mylan’s 3Q GAAP earnings of $0.36 per share declined 2.
Mylan has entered into an agreement to buy the rights to Aspen Pharmacare’s thrombosis business in Europe for EUR 641.9 million ($756.
Analysts weigh in with confidence on two biotech stocks blasting through the roof this week.
Cantor cautiously welcomes MYL’s FDA success as EPS upside; Cowen applauds CTMX’s Probody technology.
Mylan N.V.
At a time when the imminent rate hike in December has once again made investors cautious about its consequences on the investment world, …
The drama between Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) and Mylan NV (NASDAQ:MYL) continues, this time around in the courts instead of the …
In a research report issued today, Deutsche Bank analyst Gregg Gilbert maintained a Buy rating on Mylan (NASDAQ:MYL) with a $67 price target, following the …